13F Holdings
中文EN

IDXG INTERPACE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—

Margins

Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%

Returns

ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$38.73M$46.93M$40.04M$31.84M$8.20M
Cost of revenue$14.60M$17.00M$14.98M$13.61M$14.31M
Gross profit$24.13M$29.93M$25.06M$18.23M$18.80M
R&D expense$642,000$676,000$636,000$703,000$1.49M
SG&A expense$9.48M$9.49M$9.36M$10.97M$10.71M
Operating income$4.08M$8.11M$3.96M-$3.62M-$6.34M
Pretax income$3.77M$6.95M$2.28M-$5.84M-$7.74M
Income tax-$21.21M$4,000$17,000$29,000-$705,000
Net income$24.57M$6.70M$1.95M-$21.96M-$14.94M
EBITDA$4.51M$8.41M$4.98M-$1.06M-$962,000
EPS (basic)5.551.420.45-5.18-3.61
EPS (diluted)0.890.400.45-5.18-3.61
Weighted avg. shares (diluted)27.70M15.73M4.36M4.24M4.13M
Banking
Net interest income——-$112,000-$158,000-$496,000
Balance sheet
Cash & equivalents$2.50M$1.46M$3.50M$4.83M$3.31M
Receivables$5.65M$8.54M$5.08M$5.03M$4.67M
Inventory$1.11M$1.21M$1.23M$1.22M$825,000
Current assets$9.90M$11.77M$10.42M$12.15M$12.17M
PP&E, net$1.42M$1.36M$790,000$480,000$317,000
Goodwill————$8.43M
Intangibles———$861,000$2.13M
Total assets$33.84M$14.79M$13.12M$15.98M$38.43M
Current liabilities$5.10M$10.62M$11.44M$14.28M$15.68M
Short-term debt———$578,000$762,000
Long-term debt———$1.85M$520,000
Total debt———$2.43M$1.28M
Total liabilities$11.47M$17.01M$22.12M$32.52M$34.31M
Shareholders' equity$22.36M-$2.22M-$55.54M-$58.09M-$42.42M
Net debt———-$2.40M-$2.03M
Shares outstanding885,7084.41M4.35M4.30M4.20M
Cash flow statement
Operating cash flow$5.83M$4.65M$3.79M-$7.69M-$8.72M
Capital expenditure$356,000$876,000$470,000$322,000$354,000
Free cash flow$5.47M$3.77M$3.32M-$8.01M-$9.07M
Investing cash flow-$356,000-$876,000-$87,000$6.21M-$315,000
Financing cash flow-$4.43M-$5.81M-$5.03M$3.00M$8.98M
Depreciation & amortization$425,000$300,000$1.03M$2.56M$5.37M
Stock-based compensation$35,000$291,000$630,000$1.26M$1.25M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.